Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7455.092 | 1.0183 | 1.0220 | 1.6605 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7455.092 | 1.0315 | 1.0377 | 1.6605 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7455.092 | 0.9808 | 0.9767 | 1.6605 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7455.092 | 1.1181 | 1.1391 | 1.6605 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7455.092 | 1.0482 | 1.0576 | 1.6605 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7455.092 | 0.9650 | 0.9575 | 1.6605 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7455.092 | 0.2793 | -0.0724 | 1.6605 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7455.092 | 0.0254 | -0.7808 | 1.6605 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7455.092 | 0.0120 | -0.8605 | 1.6605 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7456.091 | 0.9275 | 0.9164 | 1.7629 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7456.091 | 0.9538 | 0.9470 | 1.7629 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7456.091 | 0.9460 | 0.9380 | 1.7629 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7456.091 | 1.0221 | 1.0249 | 1.7629 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7456.091 | 0.9920 | 0.9909 | 1.7629 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7456.091 | 0.6306 | 0.5398 | 1.7629 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7456.091 | 0.1276 | -0.3779 | 1.7629 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7456.091 | 0.0115 | -0.8411 | 1.7629 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7456.091 | 0.0065 | -0.8855 | 1.7629 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7457.09 | 0.9490 | 0.9407 | 1.7392 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7457.09 | 0.9978 | 0.9974 | 1.7392 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7457.09 | 1.0169 | 1.0193 | 1.7392 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7457.09 | 1.0041 | 1.0047 | 1.7392 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7457.09 | 1.0485 | 1.0552 | 1.7392 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7457.09 | 0.8988 | 0.8810 | 1.7392 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7457.09 | 0.1952 | -0.2182 | 1.7392 |